2. Search Result
Search Result
Pathways Recommended: Immunology/Inflammation
Results for "

Pulmonary inflammation

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

4

Inhibitory Antibodies

10

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19830
    AN3199

    		Phosphodiesterase (PDE) Inflammation/Immunology
    AN3199 is a PDE4 inhibitor with an IC50 of 94.5 nM. AN3199 can be used for the research of inflammation-associated diseases such as asthma and chronic obstructive pulmonary disease (COPD) .
    AN3199
  • HY-P990213
    Anti-Mouse/Human IL-5 Antibody (TRFK5)

    		Interleukin Related Inflammation/Immunology
    Anti-Mouse/Human IL-5 Antibody (TRFK5) is a rat-derived anti-mouse IL-5 IgG1 κ type antibody inhibitor. Anti-Mouse/Human IL-5 Antibody (TRFK5) can significantly decrease eosinophils. Anti-Mouse/Human IL-5 Antibody (TRFK5) shows potent anti- inflammation effect on pulmonary inflammation and asthma .
    Anti-Mouse/Human IL-5 Antibody (TRFK5)
  • HY-P990260
    Anti-Mouse CD86/B7-2 Antibody (GL-1)

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD86/B7-2 Antibody (GL-1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD86/B7-2. Anti-Mouse CD86/B7-2 Antibody (GL-1) can be used for the researches of inflammation and immunology, such as allergic pulmonary inflammation .
    Anti-Mouse CD86/B7-2 Antibody (GL-1)
  • HY-123936
    SR12343

    		NF-κB IKK Neurological Disease Inflammation/Immunology
    SR12343, an IKK/NF-κB inhibitor, is a NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic. SR12343 inhibits TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO, with an IC50 of 37.02 μM for TNF-α-mediated NF-κB activation. SR12343 suppresses LPS-induced acute pulmonary inflammation in mice. SR12343 can be used for research of inflammatory and degenerative diseases .
    SR12343
  • HY-W005379
    DGM

    		TGF-beta/Smad Inflammation/Immunology
    DGM is an inhibitor of the TGF-β1/Smad signaling pathway with significant antifibrotic effects. DGM inhibits the epithelial-mesenchymal transition (EMT) process in alveolar epithelial cells and slows the progression of pulmonary fibrosis in vivo by reducing lung inflammation, improving lung function, and decreasing extracellular matrix (ECM) remodeling. DGM can be used in research on idiopathic pulmonary fibrosis (IPF) and EMT-related diseases .
    DGM
  • HY-10404
    Dilmapimod
    1 Publications Verification

    SB-681323; GW 681323

    		 p38 MAPK Autophagy Inflammation/Immunology Cancer
    Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod
  • HY-174267S
    ATX-IN-2

    		Phosphodiesterase (PDE) Inflammation/Immunology
    ATX-IN-2 (Compound 25) is an orally active and potent ATX inhibitor with an IC50 value of 3.27 nM. ATX-IN-2 reduces lysophosphatidic acid (LPA) secretion. ATX-IN-2 is promising for research of ATX-mediated diseases, such as inflammation, pulmonary fibrosis .
    ATX-IN-2
  • HY-107591B
    PF-184

    		IKK Inflammation/Immunology
    PF-184 is a potent and selective IKK-2 inhibitor (IC50: 37 nM) over rhIKK-1, IKKi, and more than 30 tyrosine and serine/threonine kinases. PF-184 can be used in the research of inflammation, such as asthma and chronic obstructive pulmonary disease .
    PF-184
  • HY-161815
    Anti-inflammatory agent 89

    		Others Inflammation/Immunology
    Anti-inflammatory agent 89 (5c) inhibits all asthma features. Anti-inflammatory agent 89 exhibits a significative effect on the restoration of pulmonary structure and reduction of lung inflammation through both its corticosteroid and H2S releasing component, which is proming for research of Asthma .
    Anti-inflammatory agent 89
  • HY-10404A
    Dilmapimod tosylate

    SB-681323 tosylate; GW 681323 tosylate

    		 p38 MAPK Autophagy Inflammation/Immunology Cancer
    Dilmapimod tosylate is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod tosylate
  • HY-153192
    Nerandomilast

    BI 1015550

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .
    Nerandomilast
  • HY-153192A
    Nerandomilast dihydrate

    BI 1015550 dihydrate

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Nerandomilast (BI 1015550) dihydrate is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast (dihydrate) has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .
    Nerandomilast dihydrate
  • HY-10404R
    Dilmapimod (Standard)

    SB-681323 (Standard); GW 681323 (Standard)

    		 Reference Standards p38 MAPK Autophagy Inflammation/Immunology Cancer
    Dilmapimod (Standard) is the analytical standard of Dilmapimod. This product is intended for research and analytical applications. Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod (Standard)
  • HY-137992
    Aucuparin

    		TGF-beta/Smad Inflammation/Immunology
    Aucuparin, a natural product found in Sorbus aucuparia, inhibits pulmonary fibrosis in a bleomycin (HY-108345)-induced lung fibrosis mouse model. Aucuparin has anti-inflammatory activity and can inhibit the activation of inflammatory factors by TGF-β .
    Aucuparin
  • HY-P99550
    Tozorakimab

    MEDI-3506

    		 Interleukin Related Inflammation/Immunology
    Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
    Tozorakimab
  • HY-162929
    TP-DEA2

    		TGF-β Receptor Inflammation/Immunology
    TP-DEA2, a predictable-release Triptolide (HY-32735) prodrug, block Bleomycin-induced pulmonary fibrosis and inflammation. TP-DEA2 significantly inhibits α-SMA production .
    TP-DEA2
  • HY-B0486
    Lonidamine
    Maximum Cited Publications
    13 Publications Verification

    AF-1890; Diclondazolic Acid; DICA

    		 Hexokinase Mitochondrial Metabolism Apoptosis Parasite Inflammation/Immunology Cancer
    Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis .
    Lonidamine
  • HY-12335
    UNC0379
    5+ Cited Publications

    		 Histone Methyltransferase Inflammation/Immunology Cancer
    UNC0379 is a selective, substrate-competitive inhibitor of lysine methyltransferase SETD8 (KMT5A) with an IC50 of 7.3 μM, KD value of 18.3 μM. UNC0379 can be used in the research of inflammation and cancers, such as pulmonary fibrosis, ovarian cancer, neuroblastoma .
    UNC0379
  • HY-112726
    PXS-4728A

    BI-1467335

    		 Monoamine Oxidase Inflammation/Immunology
    PXS-4728A (BI-1467335) is a potent and orally active semicarbazide-sensitive amine oxidase (SSAO) inhibitor. PXS-4728A inhibits airway inflammation. PXS-4728A has the potential for the research of chronic obstructive pulmonary disease (COPD) .
    PXS-4728A
  • HY-12335A
    UNC0379 TFA

    		Histone Methyltransferase Inflammation/Immunology Cancer
    UNC0379 TFA is a selective, substrate-competitive inhibitor of lysine methyltransferase SETD8 (KMT5A) with an IC50 of 7.3 μM, KD value of 18.3 μM. UNC0379 TFA can be used in the research of inflammation and cancers, such as pulmonary fibrosis, ovarian cancer, neuroblastoma .
    UNC0379 TFA
  • HY-N0232
    Psoralidin
    4 Publications Verification

    		 COX Lipoxygenase Notch Reactive Oxygen Species (ROS) Bacterial Cancer
    Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties . Psoralidin significantly downregulates NOTCH1 signaling. Psoralidin also greatly induces ROS generation .
    Psoralidin
  • HY-103363
    SB-328437
    1 Publications Verification

    		 CCR Thymidylate Synthase Inflammation/Immunology Cancer
    SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .
    SB-328437
  • HY-176057
    S118

    		β-catenin Inflammation/Immunology
    S118 is an orally active sphingosine-1-phosphate receptor 2 (S1P2 receptor) inhibitor. S118 prevents the binding of the S1P2 receptor to dapper1 (Dpr1), reduces the accumulation of β-catenin and blocks the nuclear translocation of the S1P2 receptor, thereby inhibiting inflammation, fibrosis, and epithelial-mesenchymal transition (EMT) and exerting anti-idiopathic pulmonary fibrosis (IPF) activity. S118 is promising for research of idiopathic pulmonary fibrosis .
    S118
  • HY-P99673
    Itepekimab

    REGN-3500; SAR-440340

    		 Interleukin Related NF-κB Inflammation/Immunology
    Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
    Itepekimab
  • HY-B0486R
    Lonidamine (Standard)

    AF-1890 (Standard); Diclondazolic Acid (Standard); DICA (Standard)

    		 Reference Standards Hexokinase Mitochondrial Metabolism Apoptosis Parasite Inflammation/Immunology Cancer
    Lonidamine (Standard) is the analytical standard of Lonidamine. This product is intended for research and analytical applications. Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis .
    Lonidamine (Standard)
  • HY-P3293A
    Lonodelestat TFA

    POL6014 TFA

    		 Elastase Inflammation/Immunology
    Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF) .
    Lonodelestat TFA
  • HY-P3293
    Lonodelestat

    POL6014

    		 Elastase Inflammation/Immunology
    Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF) .
    Lonodelestat
  • HY-172135
    PDE4-IN-26

    		p38 MAPK Phosphodiesterase (PDE) Inflammation/Immunology
    PDE4-IN-26 (Compound A5) is an orally active and highly selective PDE4 inhibitor. PDE4-IN-26 has anti-inflammatory activity and can inhibit the phosphorylation of p38 MAPK. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 can improve pulmonary inflammation, injury and fibrosis, promote sputum secretion and relieve cough in mice. PDE4-IN-26 can be used for the research of lung injury-related diseases .
    PDE4-IN-26
  • HY-19929
    Tanimilast

    CHF-6001

    		 Phosphodiesterase (PDE) NF-κB Interleukin Related CXCR CCR TNF Receptor Inflammation/Immunology
    Tanimilast (CHF-6001) is an orally active and selective phosphodiesterase 4 inhibitor (IC50=0.026 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration. Tanimilast increases cellular cAMP levels, and inhibits NF-κB signaling pathway. Tanimilast is used for the research of obstructive lung diseases .
    Tanimilast
  • HY-B0004
    Doxofylline

    		Adenosine Receptor Phosphodiesterase (PDE) Reactive Oxygen Species (ROS) Inflammation/Immunology
    Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
    Doxofylline
  • HY-114374
    RO5461111

    		Cathepsin Inflammation/Immunology
    RO5461111 a highly specific and orally active antagonist of Cathepsin S with IC50s of 0.4 nM (human Cathepsin S) and 0.5 nM (murine Cathepsin S), respectively. RO5461111 can effectively inhibit the activation of antigen-specific T cells and B cells. RO5461111 can improve pulmonary inflammation and lupus nephritis .
    RO5461111
  • HY-W011733
    Tulobuterol hydrochloride
    2 Publications Verification

    C-78

    		 Adrenergic Receptor Influenza Virus Antibiotic Infection Inflammation/Immunology Endocrinology
    Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol hydrochloride is also a sympathomimetic agent used as a transdermal patch, increases normal diaphragm muscle strength . Tulobuterol hydrochloride inhibit rhinovirus replication and modulate airway inflammation .
    Tulobuterol hydrochloride
  • HY-N0232R
    Psoralidin (Standard)

    		Reference Standards COX Lipoxygenase Notch Reactive Oxygen Species (ROS) Bacterial Cancer
    Psoralidin (Standard) is the analytical standard of Psoralidin. This product is intended for research and analytical applications. Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties . Psoralidin significantly downregulates NOTCH1 signaling. Psoralidin also greatly induces ROS generation .
    Psoralidin (Standard)
  • HY-145532
    S-Allylmercaptocysteine

    		Apoptosis NF-κB Keap1-Nrf2 Inflammation/Immunology Cancer
    S-allylmercaptocysteine, an organic sulfur compound extracted from garlic, has anti-inflammatory and anti-oxidative effects for various pulmonary diseases. S-allylmercaptocysteine achieves its anti-cancer effect through a variety of pathways such as inducing the apoptosis of cancer cells through the TGF-β signaling pathway, or reducing the NF-κB activity and up-regulating Nrf2 to achieve the effects of anti-inflammation and anti-oxidation .
    S-Allylmercaptocysteine
  • HY-W011733R
    Tulobuterol hydrochloride (Standard)

    C-78 (Standard)

    		 Reference Standards Adrenergic Receptor Influenza Virus Antibiotic Infection Inflammation/Immunology Endocrinology
    Tulobuterol (hydrochloride) (Standard) is the analytical standard of Tulobuterol (hydrochloride). This product is intended for research and analytical applications. Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol hydrochloride is also a sympathomimetic agent used as a transdermal patch, increases normal diaphragm muscle strength . Tulobuterol hydrochloride inhibit rhinovirus replication and modulate airway inflammation .
    Tulobuterol hydrochloride (Standard)
  • HY-B0004R
    Doxofylline (Standard)

    		Reference Standards Adenosine Receptor Phosphodiesterase (PDE) Reactive Oxygen Species (ROS) Inflammation/Immunology
    Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
    Doxofylline (Standard)
  • HY-N8278
    Dermatan sulphate sodium
    1 Publications Verification

    		 Thrombin Cardiovascular Disease Inflammation/Immunology
    Dermatan sulphate sodium is an oral active glycosaminoglycan and thrombin inactivator with antithrombotic activity. It selectively catalyzes the heparin cofactor II-mediated inactivation of thrombin without interacting with antithrombin III. Dermatan sulphate sodium promotes stem cell differentiation, exhibits high bioavailability, and alleviates pulmonary fibrosis injury induced by Bleomycin (HY-108345). Dermatan sulphate sodium can be used in research related to cardiovascular diseases, inflammation, and stem cell differentiation .
    Dermatan sulphate sodium
  • HY-N0512
    Loganin
    5 Publications Verification

    Loganoside

    		 Reactive Oxygen Species (ROS) TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    Loganin is a type of iridoid glycoside compound that possesses anti-inflammatory, antioxidant, and antitumor properties, and offers protective effects against acute lung injury and pulmonary fibrosis. Loganin exerts its protective effects against LPS (HY-D1056)-mediated inflammation and oxidative stress by upregulating the Nrf2/HO-1 signaling pathway, and it reduces neuroinflammation caused by spinal cord injury (SCI) .
    Loganin
  • HY-19638AR
    Cangrelor tetrasodium (Standard)

    		P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    Cangrelor (tetrasodium) (Standard) is the analytical standard of Cangrelor (tetrasodium). This product is intended for research and analytical applications. Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
    Cangrelor tetrasodium (Standard)
  • HY-19638A
    Cangrelor tetrasodium
    3 Publications Verification

    AR-C69931MX tetrasodium

    		 P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
    Cangrelor tetrasodium
  • HY-145581
    Mitiperstat

    AZD4831

    		 Glutathione Peroxidase Cytochrome P450 Cardiovascular Disease Inflammation/Immunology
    Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease .
    Mitiperstat
  • HY-123461
    Sul-121 hydrochloride

    		NF-κB Inflammation/Immunology
    Sul-121 hydrochloride is a novel compound with anti-oxidative capacity that effectively inhibits airway inflammation and hyperresponsiveness (AHR) in experimental models of chronic obstructive pulmonary disease (COPD). Sul-121 hydrochloride prevents lipopolysaccharide-induced airway neutrophilia and AHR in a dose-dependent manner. Sul-121 hydrochloride also demonstrates the ability to reduce oxidative stress markers in human airway smooth muscle cells. Sul-121 hydrochloride inhibits nuclear translocation of the NF-κB subunit, p65, thereby diminishing pro-inflammatory cytokine release.
    Sul-121 hydrochloride
  • HY-N0671
    Rhapontin
    2 Publications Verification

    Rhaponiticin

    		 Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin
  • HY-N0031R
    Plantamajoside (Standard)

    		Reference Standards NF-κB PI3K Apoptosis Autophagy p38 MAPK Src Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Plantamajoside (Standard) is the analytical standard of Plantamajoside. This product is intended for use in research and analytical applications. Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .
    Plantamajoside (Standard)
  • HY-N0031
    Plantamajoside
    2 Publications Verification

    		 NF-κB PI3K Akt Apoptosis Autophagy p38 MAPK Src Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .
    Plantamajoside
  • HY-N2429
    Sphondin

    		COX Inflammation/Immunology
    Sphondin possesses an inhibitory effect on IL-1β-induced increase in the level of COX-2 protein and PGE2 release in A549 cells .
    Sphondin
  • HY-147742
    Thi-DPPY

    		JAK Inflammation/Immunology
    Thi-DPPY (compound 8e) is a potent and orally active JAK3 inhibitor with IC50 values of 62.4, 1.38 nM for BTK, JAK, respectively. Thi-DPPY shows anti-proliferative activity against HBE cells. Thi-DPPY shows anti-inflammatory activity in vivo. Thi-DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .
    Thi-DPPY
  • HY-171804
    Linvemastat

    FP-020

    		 MMP Inflammation/Immunology
    Linvemastat (Compound FC-4) is an orally active MMP-12 inhibitor (IC50: < 10  nM) with high selectivity of MMP-1, -2, -3, -7, -9, -10 and -14. Linvemastat significantly attenuates lung fibrosis in Bleomycin (HY-108345) induced unilateral lung fibrosis mice model and potently reduces kidney damage, interstitial inflammation or fibrosis in kidney fibrosis model of unilateral ureteral occlusion. Linvemastat can be used for inflammatory diseases research, such as idiopathie pulmonary fibrosis (IPF), inflammatory bowel disease (IBD) and asthma .
    Linvemastat
  • HY-N0512R
    Loganin (Standard)

    Loganoside (Standard)

    		 Reference Standards Apoptosis Keap1-Nrf2 TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    Loganin (Standard) is the analytical standard of Loganin. This product is intended for research and analytical applications. Loganin is a type of iridoid glycoside compound that possesses anti-inflammatory, antioxidant, and antitumor properties, and offers protective effects against acute lung injury and pulmonary fibrosis. Loganin exerts its protective effects against LPS (HY-D1056)-mediated inflammation and oxidative stress by upregulating the Nrf2/HO-1 signaling pathway, and it reduces neuroinflammation caused by spinal cord injury (SCI) .
    Loganin (Standard)
  • HY-127110
    AK106-001616

    		Phospholipase Others Neurological Disease Inflammation/Immunology
    AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC50=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis .
    AK106-001616

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: